Clinical Trial

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-01-02; most recent amendment 2026-06-30.
Trial Details
NCT Number NCT06189963
Lead Sponsor NKGen Biotech, Inc.
Conditions Moderate Alzheimer Disease
Enrollment 36 participants
Start Date 2023-11-21
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-02